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Small Molecule Inhibitor Design for
Anaplastic Lymphoma Kinase Inhibition
THEODORE D. HANSEL, DAVID J. GRABOVSKY
The Anaplastic Lymphoma Kinase (ALK) gene has been linked to tumorigenesis in a number of
human cancers, including anaplastic large cell lymphoma (ALCL) and neuroblastoma. While ALK
mutations in ALCL and many other cancers occur as a result of gene fusions with wild type kinase
domains, those in neuroblastoma stem from single nucleotide polymorphisms (SNPs) in the kinase
domain. These lead to autophosphorylation and constitutive signaling by ALK for cell growth and
division, ultimately causing cancer. Crizotinib, an ATP-competitive ALK inhibitor, has proven to be an
effective inhibitor of both ALKWT and ALKMutant kinase domains, and is in the middle of clinical trials for
neuroblastoma treatment. This review used the PyMOL and AutoDock Vina computational biology
programs to predict the binding affinities of Crizotinib, Ceritinib (LDK378), and PF-922 to three different
ALK kinase mutations in order to determine the most effective inhibitor. The EGFR inhibitors gefitinib
and erlotinib were also analyzed in complex with ALK as negative controls to verify the specificity of the
ALK inhibitors. The crystalline complexes were then qualitatively analyzed to uncover the mechanics
behind the docking results. Based on the results generated by Vina, PF-922, representative of the second
generation of ALK inhibitors, is predicted to be the most effective out of the tested compounds. These
results may be used to predict the inhibitor that will require the lowest dosage to achieve the greatest
inhibitory effect, hopefully leading to fewer side effects from treatment.

Introduction
The Anaplastic Lymphoma Kinase (ALK) receptor
tyrosine kinase has been implicated as a major oncogene in
a variety of different cancers, ranging from adult non-small
cell lung cancer (NSCLC) and anaplastic large-cell
lymphoma (ALCL) to neuroblastoma in children1. The
majority of these mutations are fusion proteins, such as
NPM-ALK in ALCL2 or EML4-ALK in NSCLC3. In these
fusion proteins, the ALK kinase domain generally remains
intact and wild type. However, ALK mutations in
neuroblastoma are unique as they are frequently point
mutations within the kinase domain. The mutations may be
somatic or germline, with those causing tumorigenesis
leading to constitutively active kinase domains4. Crizotinib
is a dual ALK/MET inhibitor produced by Pfizer, and was
one of the first ALK inhibitors introduced. Although first
used with non-mutated (WT) ALK kinase domains in
NSCLC, Crizotinib has also demonstrated efficacy
preclinically in ALKMut cell lines, and clinically in Phase I
clinical trial patients5.
For the purposes of this review, the PyMOL and
AutoDock Vina computational programs were used to
compare the binding affinity of Crizotinib with that of ATP,
the natural ligand, as well as other ALK inhibitors. These
other inhibitors include Ceritinib (LDK378) produced by

Novartis, and a second-generation ALK inhibitor designed
by Pfizer called PF-06463922 (PF-922). All of these inhibitors
are ATP-competitive and function by binding preferentially
to the ALK kinase domain and preventing ATP from
entering the binding pocket, inhibiting the kinase activity.
Theoretically, a higher binding affinity correlates with
greater efficacy and reduced dosages to achieve the same
inhibitory effect. In vitro, this effect would be shown by
measuring ALK inhibition through western blotting or
ELIZA assays. This review analyzes the binding affinities
associated with each ligand, in addition to one designed for
this study, for three different ALK point mutations. The
first, C1097S, is used as a stand-in for the WT kinase
domain found in ALK fusion proteins. This mutation
stabilizes the model of the ALK kinase domain, and is
found in all other models of the protein6. The R1275Q
mutation represents the most common neuroblastoma
mutation, while the F1174L mutation is the most resistant
mutation commonly seen in the clinical setting7.

Methods
AutoDock Vina is a molecular docking program
that takes in the molecular structures of a receptor and a
ligand, runs computations simulating the ligand’s docking
into a specified binding pocket on the receptor, and predicts
the ligand’s binding affinity to its receptor8. Using
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structures for the C1097S, R1275Q, and F1174L ALK
mutations6, as well as for each inhibitor9–11, a docking
analysis in Vina for each ligand-receptor pairing was run to
determine binding affinities for each pairing. Vina also
produces files containing the ligand’s docked pose
responsible for the reported affinity; these files were opened
in the PyMOL molecular viewer and analyzed qualitatively
in terms of their conformations.
Before running Vina, special .pdbqt files describing
each molecule involved in docking were prepared. PDB
files (descriptions of the spatial arrangement and types of
atoms in a molecule) containing each compound’s structure
were downloaded from pdb.org and isolated in PyMOL.
ALKWT was downloaded in complex with a piperidinecarboxamide inhibitor6, which was removed; the other two
ALK mutations were downloaded in apo 6 (ligand-free)
form. All three drugs (Crizotinib, Ceritinib, and PF-922)
were originally downloaded in complex with ALK9–11,
which was subsequently removed from each ligand.

Vina’s output takes the form of .pdbqt files
containing each ligand’s 9 most likely docking poses, as
well as the log of the 9 affinities corresponding to those
poses. The .pdbqt files were saved for visualization and
comparative analysis, and only the highest affinity for each
docking run, representing the ligand’s most likely pose, was
recorded. Because Vina uses a random seed for each
docking run, its results are nondeterministic; the program
must therefore run several times for each ligand-receptor
pairing to produce reliable data. Affinities from 10 docking
runs were recorded in a Microsoft Excel spreadsheet and
then averaged to produce each pairing’s mean affinity.

Results: Computational Analysis

Figures 1 – 5 below summarize the results of our
study, listing each ligand’s binding affinities to all three
proteins (A), followed by images of the ligands docked with
each of the three versions of ALK: C1097S (B), R1275Q (C),
and F1174L (D). Figure 1 shows data on ATP, Figure 2 on
Crizotinib, Figure 3 on Ceritinib, Figure 4 on PF-922, and
Each ligand file was then opened in AutoDockTools Figure 5 on TDH-01, a drug designed by one of the authors
(ADT), a GUI extension of Vina, and subsequently saved in based on the structure of PF-922.. Comparison of the
.pdbqt format, which preserves the atom locations specified ligands bound to ALKWT shows that PF-922 (Figure 4 (B))
in PDB format, but also gives each atom partial charges (q) and TDH-01 (Figure 5 (B)) both had the highest affinity,
and an AutoDock-specific atom type (t). The same was done followed by Crizotinib (Figure 2 (B)), Ceritinib (Figure 3
with each receptor; however, crystallographic water
(B)), and finally ATP (Figure 1 (B)). Binding affinities
molecules were removed and polar hydrogens were added associated with both mutated proteins exhibited the same
(as preferred by Vina) before saving each file in .pdbqt
order, with PF-922 pulling slightly ahead of TDH-01. In
format. The final step in molecule preparation involved
every simulation, ATP was the weakest binding partner.
defining a search space on the receptors where Vina would Another table summarizing our results, which compares
search for a binding pocket. Each protein was visually
ligands instead of proteins, can be found in Appendix B.
inspected in ADT until the binding site was found; the
Comparison of the receptors yielded less obvious
search space was then specified as a box around the binding
patterns. ATP bound to ALKWT (Figure 1 (B)) with a lower
site, with (x, y, z) coordinates for its center and x, y, and zaffinity than to ALKF1174L (Figure 1 (D)), but with higher
lengths for its sides.
affinity than to ALKR1275Q (Figure 1 (C)). Crizotinib did not
Once the .pdbqt files for all receptors and proteins
follow this trend, binding weakest to ALKR1275Q (Figure 2
were saved, a configuration (config) file was written and
(C)), slightly stronger to ALKF1174L (Figure 2 (D)), and
Vina was run. The config file gave Vina the filenames of the strongest to ALKWT (Figure 2 (B)), for which it was
ligand and receptor to be docked, as well as the coordinates designed. Ceritinib behaved differently, binding to
and size of the search space box found graphically in ADT. ALKR1275Q (Figure 3 (C)) with higher affinity than to
(See Appendix A for the format and parameters of the
ALKF1174L (Figure 3 (D)); yet still the bond was not as strong
config file.) Vina was run from a Windows command
as to ALKWT (Figure 3 (B)). PF-922, the overall best ALK
prompt: after changing the computer’s directory to the
inhibitor, interestingly bound with higher affinity to ALK Mut
folder where vina.exe was located, the command
proteins (Figure 4 (C-D)) than to ALKWT (Fiure 4 (B)). TDH“\Vina\vina.exe” --config conf.txt --log log.txt
01 also fared better with mutated proteins (Figure 5 (C-D))
read the config file and created a log of its output as the
than with ATPWT (Figure 5 (A)), actually binding best to the
analysis ran.
notoriously resistant ALKF1174L (Figure 5 (D)). These trends
in PF-922 and TDH-01 show their functional similarity, as
well as their specificity for mutated ALK variants.
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TDH-01 was designed by one of the authors based
on the PF-922 geometry, and attempted to gain a higher
The binding affinity between a protein and its
binding affinity than PF-922 by creating more regions of
ligand are a direct result of how tightly the ligand fits into
high electronegativity in the molecule. While TDH-01
its binding pocket, as well as how well the ligand matches
interacted with many of the same hot spots as PF-922 and
“hot spots” in the pocket. Hot spots are regions in the
had a nearly identical docking pose, the additional
protein of high electrical charge that can create strong
electronegativity also increased its repulsion of the binding
intermolecular forces to hold the ligand inside the binding
pocket’s negatively charged regions. While also present in
site. As previously noted, all of the inhibitors demonstrated ALKWT and ALKF1174L (figure 5 (D)), this is especially evident
a greater binding affinity than ATP for all ALK mutations,
with the proximity of the anterior nitrogen atoms and the
which is necessary for the inhibitor to function. By
negative region of ALKR1275Q (figure 5 (C)). Figure 6 below is
analyzing the crystal structure of the inhibitors in complex
a side-by-side comparison of the structures of PF-922 (A)
with the ALK kinase domain, it becomes clear that the more and TDH-01 (B). The increased polarity within TDH-01, as
effective compounds, such as PF-922, TDH-01, and
evidenced by the abundance of fluorine, nitrogen, and
Crizotinib, bind more preferably than Ceritinib or ATP.
oxygen atoms, is most likely liable for its slight decrease in
binding affinity.
Figure 1 (B) shows the crystalline structure of ATP
in the WT kinase domain. The fit of the molecule inside the
pocket is relatively loose, and there are only a few hotspots
linked to electronegative regions in the molecule. These
explain the relatively low binding affinity. There are even
some electronegative regions of the molecule near negative
hotspots, which would suggest repulsion. These same
principles are also evident in ALKR1275Q in figure 1 (C) and
ALKF1174L in figure 1 (D). Crizotinib, shown in complex with
ALKWT in figure 2 (B), has a similar linear structure to that
of ATP, but features a highly electronegative fluorine
attached to an aromatic ring, giving it the ability to bind
with a hot spot in the pocket ATP was unable to reach,
Discussion and Conclusion
likely giving Crizotinib its preferential affinity. Crizotinib
also binds strongly to this hotspot in both ALKR1275Q (figure
Based on our results, PF-922 is predicted to be the
2 (C)) and ALKF1174L (figure 2 (D)). Ceritinib also binds more
most
effective
ALK inhibitor, especially for the resistant
preferentially than ATP to all three ALK mutations (Figure
F1174L mutation. Our data matches that of other published
3). Since Ceritinib does not appear to directly bind with
studies9. Additionally, the protein models accurately reflect
many hot spots, its increased affinity is likely due to a
the observed in vitro resistance of the F174L ALK mutation
tighter fit than ATP’s, although it also features a linear
12
structure similar to ATP and Crizotinib but lacks the highly due to its increased ATP binding affinity . This review has
demonstrated the beneficial effect of not only
interactive fluorine.
conformational compatibility, but also hotspot targeting in
PF-922, representing the second generation ALK
rational drug design. The inhibitors that demonstrated the
inhibitors, displays the highest binding affinity out of all of highest binding affinities were those with the greatest
the reviewed inhibitors (figure 4 (A)). Like Crizotinib, it
amount of conformity to the pocket and those which
features the aromatic ring-linked fluorine to strongly bind
targeted the most hotspots.
to hot spots, but departs from the linear design in favor of a
The most obvious path for future research is
ringed shape. Resulting in an altogether wider molecule in
preclinical
and clinical testing of these compounds.
the main horizontal plane, PF-922 fits more snugly into the
Crizotinib has already proven its efficacy in the clinical
binding pocket than the other inhibitors, allowing it gain a
stronger affinity to the walls of the pocket while interacting setting, and the other drugs are also ambling in this
direction. TDH-01, at present only a theoretical model,
with particular hotspots (figure 4 (B-D)).
would have to be produced in the laboratory prior to any
bench testing. While direct clinical or preclinical
comparisons of these compounds are unlikely, this review

Qualitative Comparison

—4—

serves as a good basis for the comparison of ALK inhibitor
efficacy from computational and qualitative perspectives.
Computational results gathered during preclinical testing of
new compounds allows researchers to better focus on
testing drugs with higher chances of success, allowing for
more efficient use of limited research funding. The current

process for drug design (high throughput screening) is not
only laborious, but also incredibly expensive. By integrating
data gathered through computational methods,
pharmaceutical engineers may more intelligently create
drugs, streamlining the development and production of
more effective novel treatments.
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Appendix A: The Configuration File
receptor = filename.pdbqt
ligand = filename.pdbqt
out = out.pdbqt
center_x = 20.0
center_y = 15.0
center_z = variable:
C1097S: 63
R1275Q: 10
F1174L: 11
size_x = 20
size_y = 20
size_z = 20
exhaustiveness = 8

Appendix B: Average Inhibitor Binding Affinities
Inhibitors
(kcal/mol)

ATP

Ceritinib

Crizotinib

PF-922

TDH-01

C1097S

6.81

7.9

8.19

9.20

9.20

R1275Q

6.39

7.51

7.92

10.40

9.70

F1174L

6.94

7.43

7.99

10.40

10.10

Negative Controls
Gefitinib

Erlotinib

C1097S

7.61

6.55

R1275Q

7.22

6.66

F1174L

7.50

6.65

(kcal/mol)

Note: All binding affinities listed above and in Figures 1 – 5 are given in terms of the energy released as binding occurs.
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